<div id="readability-page-1"><p>Cencora, Inc. (NYSE:COR - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Friday after Wells Fargo &amp; Company raised their price target on the stock from $236.00 to $249.00. Wells Fargo &amp; Company currently has an equal weight rating on the stock. Cencora traded as high as $247.66 and last traded at $247.57, with a volume of 3243856 shares. The stock had previously closed at $244.46.</p><ul><li>Teva Pharma is the way to play the re-rise of generic drugs </li></ul><p>COR has been the topic of several other reports. StockNews.com downgraded shares of Cencora from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Thursday, May 2nd. Citigroup lifted their price objective on shares of Cencora from $265.00 to $280.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, April 30th. Robert W. Baird lifted their price objective on shares of Cencora from $285.00 to $287.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday. Finally, SVB Leerink reiterated an &#34;outperform&#34; rating and issued a $275.00 price objective on shares of Cencora in a research note on Thursday, June 27th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $243.00.</p><p><b>View Our Latest Research Report on Cencora</b></p><h2>Insider Activity at Cencora</h2><ul><li>Eli Lilly, McKesson, Novartis Flash Promising Chart Action </li></ul><p>In other news, Director Dermot Mark Durcan acquired 500 shares of the stock in a transaction that occurred on Friday, May 24th. The shares were acquired at an average cost of $218.58 per share, for a total transaction of $109,290.00. Following the purchase, the director now owns 21,876 shares of the company's stock, valued at approximately $4,781,656.08. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. In other news, CEO Steven H. Collis sold 10,755 shares of the company's stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at $63,323,746.56. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Dermot Mark Durcan purchased 500 shares of the firm's stock in a transaction dated Friday, May 24th. The shares were bought at an average price of $218.58 per share, for a total transaction of $109,290.00. Following the completion of the transaction, the director now owns 21,876 shares of the company's stock, valued at $4,781,656.08. The disclosure for this purchase can be found here. In the last three months, insiders have sold 1,899,112 shares of company stock worth $408,654,376. Company insiders own 15.80% of the company's stock. </p><h2>Institutional Investors Weigh In On Cencora</h2><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. Fisher Asset Management LLC bought a new position in shares of Cencora in the fourth quarter worth approximately $244,000. Trust Co. of Vermont bought a new position in shares of Cencora in the fourth quarter worth approximately $62,000. Wahed Invest LLC bought a new position in shares of Cencora in the fourth quarter worth approximately $567,000. Vanguard Group Inc. bought a new position in shares of Cencora in the fourth quarter worth approximately $4,212,508,000. Finally, Hennessy Advisors Inc. bought a new position in shares of Cencora in the fourth quarter worth approximately $3,307,000. 97.52% of the stock is currently owned by institutional investors. </p><h2>Cencora Stock Performance</h2><ul><li>3 High Dividend REITs That Analysts Are Bullish On</li></ul><p>The company has a market capitalization of $49.38 billion, a P/E ratio of 26.74, a PEG ratio of 1.65 and a beta of 0.45. The company's 50-day moving average is $228.28 and its two-hundred day moving average is $230.99. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41. </p><p>Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 271.72% and a net margin of 0.65%. Cencora's revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.92 earnings per share. Equities analysts anticipate that Cencora, Inc. will post 13.47 earnings per share for the current fiscal year. </p><h2>Cencora Dividend Announcement</h2><p>The company also recently announced a quarterly dividend, which will be paid on Monday, August 26th. Shareholders of record on Friday, August 9th will be paid a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend is Friday, August 9th. Cencora's dividend payout ratio is currently 22.32%. </p><h2>Cencora Company Profile</h2> (Get Free Report)<p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p><h2>Read More</h2><ul><li>Five stocks we like better than Cencora</li><li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li><li>Should You Invest in Bitcoin? Pros and Cons</li><li>Top Stocks Investing in 5G Technology</li><li>Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts</li><li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li><li>Shell Stock: Oil &amp; Gas Giant Committed to Buybacks and Dividends</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Unveiled: NVIDIA’s &#34;Secret Royalty&#34; Program <span><span>(From Behind the Markets)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDM5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDM5"/></p><h2>Should you invest $1,000 in Cencora right now?</h2><p>Before you consider Cencora, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p><p>While Cencora currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

<p>Cencora (NYSE:COR) reached a new 12-month high following an analyst upgrade from Wells Fargo. The stock traded as high as $247.66 and closed at $247.57. Several other reports also provided positive ratings and increased price targets for Cencora. The company's market capitalization is $49.38 billion, with a P/E ratio of 26.74. The company reported earnings per share of $3.34 for the quarter, beating analyst estimates. The stock is currently rated as a "Moderate Buy" with an average target price of $243.00.</p>

Cencora (NYSE:COR) Sets New 12-Month High on Analyst Upgrade